Skip to main content

Table 2 Clinicopathological features of epithelial ovarian cancer patients of all 12 cases

From: Differences in immune-related gene expressions and tumor-infiltrating lymphocytes according to chemotherapeutic response in ovarian high-grade serous carcinoma

Case Age FIGO stage Pathologic diagnosis CTx regimen Follow-up period (mo) Time of recurrence after CTx (mo) Response group Status of survival
1 42 IIIc HGSC Carbo-Taxol 15 4 CR No
2 63 IV HGSC Carbo-Taxol 29 8 CR No
3 79 IIIc HGSC Carbo-Taxol 17 4 CR N/A
4 66 IIIc HGSC Carbo-Taxol 29 Progression during CTx CR N/A
5 62 IV HGSC Carbo-Taxol 10 1 CR No
6 73 IV HGSC Carbo-Taxol 30 Relapse within CTx CR Yes
7 64 IIIc HGSC Carbo-Taxol 35 No relapse CS Yes
8 55 IIIc HGSC Carbo-Taxol 51 No relapse CS Yes
9 62 IIIc HGSC Carbo-Taxol 64 No relapse CS Yes
10 69 IIa HGSC Carbo-Taxol 39 32 CS Yes
11 50 IIIc HGSC Carbo-Taxol 24 No relapse CS Yes
12 49 IV HGSC Carbo-Taxol 75 19 CS Yes
  1. FIGO the International Federation of Gynecology and Obstetrics, HGSC High-grade serous carcinoma, CTx chemotherapy, Carbo-Taxol carboplatin and paclitaxel, mo month, CR chemoresistant, CS chemosensitive, N/A not applicable